- The FDA has granted Emergency Use Authorization (EUA) to Talis Biomedical Corporation's TLIS Talis One COVID-19 Test System, a nucleic acid amplification test (NAAT).
- The Talis One system enables sample-to-answer molecular testing in less than 30 minutes.
- The Talis One COVID-19 Test System targets two genes, ORF1ab and N. Designed for cloud connectivity, the instrument is being further developed to enable easy results sharing and simplified patient data management in the future.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: TLIS shares are up 11.4% at $5.88 during the market session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
